Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Oncogene

• Publication date

  2007-04-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.onc.1210034PMID 17043649
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation

  2006influential reference
• RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.

  2006cited by this paper
• A survey of the signaling pathways involved in megakaryocytic differentiation of the human K562 leukemia cell line by molecular and c-DNA array analysis

  2006influential reference
• Fast apoptosis and erythroid differentiation induced by imatinib mesylate in JURL‐MK1 cells

  2005cited by this paper
• Vital functions for lethal caspases

  2005cited by this paper
• PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

  2005cited by this paper
• Nuclear substructure reorganization during late-stage erythropoiesis is selective and does not involve caspase cleavage of major nuclear substructural proteins.

  2005cited by this paper
• Caspase-3 has a nonapoptotic function in erythroid maturation.

  2004influential reference
• A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity.

  2004influential reference
• Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis

  2004cited by this paper
• Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it

  2004cited by this paper
• Different roles of p38 MAPK and ERK in STI571‐induced multi‐lineage differentiation of K562 cells

  2004cited by this paper
• The BCR-ABL story: bench to bedside and back.

  2004cited by this paper
• Role of the p38 Mitogen-activated Protein Kinase Pathway in the Generation of the Effects of Imatinib Mesylate (STI571) in BCR-ABL-expressing Cells*

  2004cited by this paper
• JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

  2004cited by this paper
• Specific inhibition of bcr-abl gene expression by small interfering RNA.

  2003influential reference
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003cited by this paper
• Caspase activation is not death

  2003cited by this paper
• The protein tyrosine phosphatase HePTP regulates nuclear translocation of ERK2 and can modulate megakaryocytic differentiation of K562 cells

  2003cited by this paper
• A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.

  2003cited by this paper
• STI-571: an anticancer protein-tyrosine kinase inhibitor.

  2003cited by this paper
• Imatinib induces mitochondria‐dependent apoptosis of the Bcr‐Abl‐positive K562 cell line and its differentiation toward the erythroid lineage 1

  2003influential reference
• Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).

  2003cited by this paper
• Specific inhibition of gene expression using a stably integrated, inducible small‐interfering‐RNA vector

  2003cited by this paper
• Raf-1 Antagonizes Erythroid Differentiation by Restraining Caspase Activation

  2002cited by this paper
• Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2.

  2002cited by this paper
• A Potential Role for Protein Kinase C-ε in Regulating Megakaryocytic Lineage Commitment*

  2001influential reference
• A potential role for protein kinase C-epsilon in regulating megakaryocytic lineage commitment.

  2001influential reference
• Caspase Activation Is Required for Terminal Erythroid Differentiation

  2001cited by this paper
• Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

  2000cited by this paper
• Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

  2000cited by this paper
• The molecular biology of chronic myeloid leukemia.

  2000cited by this paper
• Differential expression of the Kell blood group and CD10 antigens: two related membrane metallopeptidases during differentiation of K562 cells by phorbol ester and hemin

  1998influential reference

• Tackling Imatinib Resistance via Au‐nanoconjugates using A Cml Resistant Cell Line

  2023cites this paper
• Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia

  2021cites this paper
• Perturbation of p38α MAPK as a Novel Strategy to Effectively Sensitize Chronic Myeloid Leukemia Cells to Therapeutic BCR-ABL Inhibitors

  2021influential citation
• Cabozantinib promotes erythroid differentiation in K562 erythroleukemia cells through global changes in gene expression and JNK activation

  2021cites this paper
• Ultra-small platinum nanoparticles on gold nanorods induced intracellular ROS fluctuation to drive megakaryocytic differentiation of leukemia cells.

  2020cites this paper
• A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway

  2020influential citation
• Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL

  2019cites this paper
• A systems biology pipeline identifies regulatory networks for stem cell engineering

  2019cites this paper
• Metabolic Reprogramming During Multidrug Resistance in Leukemias

  2018cites this paper
• Montelukast enhances cytocidal effects of carfilzomib in multiple myeloma by inhibiting mTOR pathway

  2018cites this paper
• Targeting the Process of C-MYC Stabilization in Chronic Myelogenous Leukemia

  2018cites this paper
• Combined MEK and Pi3′-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo

  2017cites this paper
• In Vitro and in Vivo Evaluation of Fully Substituted (5-(3-Ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as Original Nucleoside Analogues to Circumvent Resistance in Myeloid Malignancies.

  2017cites this paper
• Suppression of c-Myc induces apoptosis via an AMPK/mTOR-dependent pathway by 4-O-methyl-ascochlorin in leukemia cells

  2016cites this paper
• p38MAPK and Chemotherapy: We Always Need to Hear Both Sides of the Story

  2016cites this paper
• Differentiation inducing factor 3 mediates its anti-leukemic effect through ROS-dependent DRP1-mediated mitochondrial fission and induction of caspase-independent cell death

  2016cites this paper
• Down-regulation of superoxide dismutase 1 by PMA is involved in cell fate determination and mediated via protein kinase D2 in myeloid leukemia cells.

  2015cites this paper
• BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients

  2012cites this paper
• All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib

  2012cites this paper
• The caspase 6 derived N-terminal fragment of DJ-1 promotes apoptosis via increased ROS production

  2012cites this paper
• A New Hydroxylated Nonaprenylhydroquinone from the Mediterranean Marine Sponge Sarcotragus spinosulus

  2011cites this paper
• Leukemic cell xenograft in zebrafish embryo for investigating drug efficacy

  2011cites this paper
• BJ-B11, a novel Hsp90 inhibitor, induces apoptosis in human chronic myeloid leukemia K562 cells through the mitochondria-dependent pathway.

  2011cites this paper
• MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia

  2011cites this paper
• Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR–ABL

  2011cites this paper
• Azacitidine-resistant SKM1 myeloid cells are defective for AZA-induced mitochondrial apoptosis and autophagy

  2011cites this paper
• Mechanism of action of the multikinase inhibitor Foretinib

  2011cites this paper
• Role of p38α in apoptosis: implication in cancer development and therapy

  2011cites this paper
• Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation.

  2010cites this paper
• Induction of apoptosis and lipogenesis in human preadipocyte cell line by n −3 PUFAs

  2010cites this paper
• Involvement of ERK1/2, p38 and PI3K in megakaryocytic differentiation of K562 cells

  2010cites this paper
• Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells

  2010cites this paper
• Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR–ABL cleavage and elimination of chronic myelogenous leukemia cells

  2010cites this paper
• Effect of genistein and daidzein on the proliferation and differentiation of human preadipocyte cell line.

  2010cites this paper
• Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.

  2010cites this paper
• Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells

  2009cites this paper
• Pml and TAp73 interacting at nuclear body mediate imatinib‐induced p53‐independent apoptosis of chronic myeloid leukemia cells

  2009cites this paper
• Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.

  2009cites this paper
• A non‐apoptotic function of caspase‐3 in pharmacologically‐induced differentiation of K562 cells

  2009cites this paper
• C3G silencing enhances STI-571-induced apoptosis in CML cells through p38 MAPK activation, but it antagonizes STI-571 inhibitory effect on survival.

  2009cites this paper
• RESEARCH PAPER A non-apoptotic function of caspase-3 in pharmacologically-induced differentiation of K562 cells

  2009cites this paper
• Acadesine Kills Chronic Myelogenous Leukemia (CML) Cells through PKC-Dependent Induction of Autophagic Cell Death

  2009cites this paper
• Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors

  2009cites this paper
• Imatinib mesylate‐resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol

  2008cites this paper
• STI571/doxorubicin concentration-dependent switch for diverse caspase actions in CML cell line K562.

  2008cites this paper
• Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment.

  2007cites this paper
• ERK1/2 inactivation and p38 MAPK-dependent caspase activation during guanosine 5'-triphosphate-mediated terminal erythroid differentiation of K562 cells.

  2007cites this paper
• Arsenic sul fi de nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL

  year unknowncites this paper